These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19339077)

  • 21. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
    Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
    Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
    Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients.
    Carrillo-de Santa Pau E; Carrillo Arias F; Caso Pelaez E; Muguruza Trueba I; Sánchez Hernández I; Muñoz Molina GM; Moreno Balsalobre R; Sacristán López S; Gómez-Pinillos A; Toledo Lobo Mdel V
    Cancer Invest; 2010 May; 28(4):393-8. PubMed ID: 19968501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)].
    Huang F; Wang XL; Geng Y; Li MX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):507-9. PubMed ID: 15989803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
    Tamura M; Ohta Y
    Cancer; 2003 Sep; 98(6):1217-22. PubMed ID: 12973845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
    Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
    O'Byrne KJ; Koukourakis MI; Giatromanolaki A; Cox G; Turley H; Steward WP; Gatter K; Harris AL
    Br J Cancer; 2000 Apr; 82(8):1427-32. PubMed ID: 10780522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer.
    Ren H; Tang X; Lee JJ; Feng L; Everett AD; Hong WK; Khuri FR; Mao L
    J Clin Oncol; 2004 Aug; 22(16):3230-7. PubMed ID: 15310766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
    Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
    Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
    Hsu WH; Huang CS; Hsu HS; Huang WJ; Lee HC; Huang BS; Huang MH
    Ann Thorac Surg; 2007 Feb; 83(2):419-24. PubMed ID: 17257963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
    Zhao J; Liu XY; Zhang QY; Jiang W
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer.
    Sen E; Ulger F; Kaya A; Akar N; Gonullu U
    Clin Lung Cancer; 2008 May; 9(3):166-70. PubMed ID: 18621627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
    Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
    Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
    Han JY; Choi BG; Choi JY; Lee SY; Ju SY
    Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
    Nieder C; Andratschke N; Jeremic B; Molls M
    Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.
    Donnem T; Al-Saad S; Al-Shibli K; Delghandi MP; Persson M; Nilsen MN; Busund LT; Bremnes RM
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6649-57. PubMed ID: 18006765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
    Laack E; Scheffler A; Burkholder I; Boeters I; Andritzky B; Schuch G; Görn M; Vohwinkel G; Edler L; Fiedler W; Hossfeld DK
    Lung Cancer; 2005 Oct; 50(1):51-8. PubMed ID: 15992959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.